Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Arch Biopartners Inc V.ARCH

Alternate Symbol(s):  ACHFF

Technology Scientific & Technical Instruments
Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is LSALT Peptide. The Company is engaged in the clinical development of LSALT Peptide and other DPEP-1 targeting drug candidates for indications where inflammation of the lungs, liver and kidneys is an unmet problem. LSALT Peptide is in a second phase II trial, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). The Company has additional technology platforms in its portfolio, which are AB569 and Borg. AB569 is an anti-infective candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds.


TSXV:ARCH - Post by User

Arch Biopartners Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(260)
•••
Post by Viking2233on Aug 20, 2024 9:43am
229 Views
Post# 36187609

Kidney Foundation of Canada

Kidney Foundation of CanadaI was searching the web regarding University of Calgary trying to find information on the recently announced Pontiac trial to try and get a handle on dates and applications but no such luck.

I did how ever stumble across a couple of very positive articles regarding Cilistatin which just highlights the potential upside for this re-purposed drug.

I have no doubt we have a winner here but my only concern is when the Pontiac trial will actually commence dosing. This is totally out of Arch Management's control.

I had know idea that Kidney Foundation of Canada was reporting on this which just adds additional credibility!

Enjoy the articles below:

https://kidney.ca/CMSPages/GetFile.aspx?guid=1b825978-df1e-484b-b382-760cacc04f72

https://ucalgary.ca/news/university-of-Calgary-researchers-identify-key-inflammation-pathway-that-causes-acute-kidney-injury
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities